Stock & Company Details
Fennec Pharmaceuticals Inc $FENC
Price:
N/A
N/A
35M
$378M
52 Week High:
N/A
10 Day Average Volume:
N/A
-37.86
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
FENC technical indicators
Latest Fennec Pharmaceuticals Inc (FENC) indicator readings as of 2026-09-18.
FENC's 14-day RSI is 40.7, in neutral territory. At $10.62 it is trading 21.0% above its 200-day moving average of $8.78, and below its 50-day average of $11.10. Price sits near the lower Bollinger Band ($10.23 to $12.97). ADX reads 24.2, sitting between trending and range-bound.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Finance Bot
Ask your questions
Start by typing a question below.
